NEURONTIN CAPSULE

Pajjiż: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

GABAPENTIN

Disponibbli minn:

BGP PHARMA ULC

Kodiċi ATC:

N02BF01

INN (Isem Internazzjonali):

GABAPENTIN

Dożaġġ:

100MG

Għamla farmaċewtika:

CAPSULE

Kompożizzjoni:

GABAPENTIN 100MG

Rotta amministrattiva:

ORAL

Unitajiet fil-pakkett:

100

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

MISCELLANEOUS ANTICONVULSANTS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0125929001; AHFS:

L-istatus ta 'awtorizzazzjoni:

APPROVED

Data ta 'l-awtorizzazzjoni:

2001-01-05

Karatteristiċi tal-prodott

_NEURONTIN (gabapentin) _
_Page 1 of 38_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
NEURONTIN®
Gabapentin Capsules
Capsules, 100 mg, 300 mg and 400 mg, oral
Gabapentin Tablets
Tablets, 600 mg and 800 mg, oral
Antiepileptic Agent
BGP Pharma ULC
85 Advance Road
Etobicoke (Ontario)
Canada M8Z 2S6
Date of Initial Approval:
MAY 05, 2023
Date of Revision:
OCTOBER 16, 2023
Submission Control No: 275525
®
Viatris Specialty LLC
BGP Pharma ULC, a Viatris company, Licensee
© BGP Pharma ULC, 2023
_ _
_NEURONTIN (gabapentin) _
_Page 2 of 38_
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, Dependence/Tolerance
10-2023
7.1 Special Populations, 7.1.1 Pregnant Women, Neonatal
withdrawal syndrome
02-2023
7.1 Special Populations, 7.1.1 Pregnant Women, Women of
childbearing potential/Contraception
10-2023
7.1 Special Populations, 7.1.1 Pregnant Women, Teratogenic
Potential
10-2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.............................................................................................
2
TABLE OF CONTENTS
...............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
4
1
INDICATIONS
................................................................................................................
4
1.1
Pediatrics
.................................................................................................................
4
1.2
Geriatrics
.................................................................................................................
4
2
CONTRAINDICATIONS
..................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................. 4
4
DOSAGE AND ADMINISTRATION
......................